

## REID SHAW

E-mail: reid.shaw@uchicagomedicine.org

### EDUCATION and CLINICAL TRAINING

Hematology and Oncology Fellow   University of Chicago	2024 - present
Internal Medicine Resident   Loyola University Medical Center	2021 – 2024
MD   University of Rochester School of Medicine and Dentistry	2017 - 2021
BA in Biochemistry, Biophysics, and Molecular Biology   Whitman College	2010 – 2014

### RESEARCH EXPERIENCE

Research Fellow   University of Chicago - PI: Thomas Gajewski, MD, PhD	2025 - present
Research Scholar   Loyola University Medical Center - PI: Nasheed Hossain, MD	2022 – 2024
Machine Learning Fellow   University of Rochester Medical Center - PI: Richard Moore, MD	2019 – 2021
Bioinformatician   SEngine Precision Medicine - PI: VK Gadi, MD, PhD	2016 – 2019
Research Fellow   Cure First - PI: Carla Grandori, MD, PhD	2016 – 2019
Research Assistant   Fred Hutchinson Cancer Research Center - PI: Chris Kemp, PhD	2014 – 2016
Research and Development   Mirador Biomedical - PI: Justin Hulvershorn, MD, PhD	2011 - 2014

### ONGOING RESEARCH PROJECTS

- CIBMTR study (CT22-02): Stacking machine learning algorithms to predict toxicity and clinical outcomes in patients treated with CAR-T therapy; a real-world analysis.
- Investigating the efficacy of anti-CD19 CAR-T in patients with acute lymphoblastic leukemia who harbor a BCR-ABL fusion.
- A multi-institutional study using machine learning to predict the toxicity and durable response in patients with relapsed/refractory DLBCL who received bispecific antibody therapy.
- A phase 1/2 investigator-initiated clinical trial investigating the co-administration of lactulose and immune checkpoint immunotherapy.
- Enhancing the efficacy of adoptive T cell therapy through modulation of the microbiome.

### PEER-REVIEWED PUBLICATIONS

1. Pozin J, **Shaw R**, Weiss J. Breaking the dichotomy of HER2: highlighting the flaws of simplifying variables. *Frontiers in Oncology*. 2025. PMID 40416877.
2. **Shaw R**, Yoon JJ, Johnston H, Davidson MB, Siddon AJ, Shallis RM, Chen EC, Burkart M, Oh TS, Iyer SG, Madarang E, Muthiah C, Kassner J, Rampal RK, Murthy GSG, Bradley T, Abaza Y, Garcia JS, Gupta V, Pettit KM, Odenike O, Patel AA. Assessing acute myeloid leukemia-based risk stratification criteria in patients with accelerated/blast-phase myeloproliferative neoplasms treated with less-intensive therapy. *Blood Advances*. 2025. PMID 39969200.
3. Luu T, Fan A, **Shaw R**, Dalal H, Adams J, Santarossa M, Reid G, Tsai S, Clark N, Albarillo F. Improved Clinical Outcomes with Appropriate Meropenem De-escalation in Patients with Febrile Neutropenia. *Journal of Global Infectious Disease*. 2024. PMID 39886084.

4. **Shaw R**, Zander A, Ronnie T, Azari Z, Gregorowicz A, Albarillo F. Assessing the predictive value of methicillin-resistant *Staphylococcus aureus* nares colonization amongst transplant recipients and patients with neutropenia. *Open Forum Infectious Diseases*. 2024. PMID 39050229.
5. **Shaw R**, Haque AR, Luu T, O'Connor TE, Hamidi A, Fitzsimons J, Varda B, Kwon D, Whitcomb C, Gregorowicz A, Roloff GW, Bemiss BC, Kallwitz ER, Hagen PA, Berg S. Multicenter analysis of immunosuppressive medications on the risk of malignancy following adult solid organ transplant. *Frontiers in Oncology*. 2023. PMID 37397376.
6. Hamidi A\*, Roloff GW\*, **Shaw R**, Acevedo M, Smith S, Drazer MW. Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes. *Leukemia & Lymphoma*. 2023. PMID 37294121.
7. O'Connor TE, **Shaw R**, Madero-Marroquin R, Roloff GW. Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy. *Frontiers in Oncology*. 2023. PMID 37251919.
8. Roloff GW, **Shaw R**, O'Connor TE, Drazer MW. Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies. *Journal of Medical Genetics*. 2023. PMID 36642751.
9. **Shaw R**, Lokshin AE, Miller MC, Messerlian-Lambert G, Moore RG. Stacking machine learning algorithms for biomarker-based preoperative diagnosis of a pelvic mass. *Cancers*. 2022. PMID 35267599.
10. Raman R, Villefranc J, Ullmann TM, Thiesmeyer J, Anelli V, Yao J, Hurley JR, Pauli C, Bareja R, Eng KW, Dorsaint P, Wilkes DC, Beg S, **Shaw R**, Churchill M, Ahmed A, Keefer L, Misner I, Nichol D, Gumpeni N, Scognamiglio T, Rubin MA, Grandori C, Solomon JP, Song, W, Mosquera JM, Dephoure N, Sboner A, Elemento O, Houvras Y. Inhibition of fibroblast growth factor receptor blocks adaptive resistance to RET inhibitors in CCDC6-RET rearranged thyroid cancer. *Journal of Experimental Medicine*. 2022. PMID 35510953.
11. Pauli C, De Boni L, Pauwels JE, Chen Y, Planas-Paz L, **Shaw R**, Emerling BE, Grandori C, Hopkins BD, Rubin MA. A functional precision oncology approach to identify treatment strategies for myxofibrosarcoma patients. *Molecular Cancer Research*. 2022. PMID 34728552.
12. Shigeta S, Lui GY, **Shaw R**, Moser, R, Gurley KE, Durenberger G, Rosati R, Diaz RL, Ince TA, Swisher EM, Grandori C, Kemp CJ. Targeting BET proteins BRD2 and BRD3 in combination with PI3K-AKT inhibition as a therapeutic strategy for ovarian clear cell carcinoma. *Molecular Cancer Therapeutics*. 2021. PMID 33509905.
13. Lui GY\*, **Shaw R\***, Schaub FX, Stork IN, Gurley KE, Bridgwater C, Diaz RL, Rosati R, Swan HA, Ince TA, Harding TC, Gadi VK, Goff BA, Kemp CJ, Swisher EM, Grandori C. Functional genomic screens identify SRC, BET, and BCL2 family inhibitors as novel synergistic drug combinations with the PARP inhibitor rucaparib in patient-derived ovarian cancer cells. *EBio Medicine*. 2020. PMID 32927276.
14. Puca L, Bareja R, Prandi D, **Shaw R**, Benelli M, Karthaus WR, Hess J, Sigouros M, Donoghue A, Kossai M, Gao D, Cyrta J, Sailer V, Vosoughi A, Pauli C, Churakova Y, Cheung C, Deonaraine LD, McNary TJ, Rosati R, Tagawa ST, Nanus DM, Mosquera JM, Sawyers CL, Chen Y, Inghirami G, Rao RA, Grandori C, Elemento O, Sboner A, Demichelis F, Rubin MA, Beltran H. Patient Derived Organoids to Model Rare Prostate Cancer Phenotypes. *Nature Communications*. 2018. PMID 29921838.
15. Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, **Shaw R**, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Bernard B, Grandori C. Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas. *Cell Systems*. 2018. PMID 29596783.
16. Xu C, Nikolova O, Basom R, Mitchell RM, **Shaw R**, Moser RD, Park H, Gurley KE, Kao MC, Green CL, Schaub FX, Diaz RL, Swan HA, Jang IS, Guinney J, Gadi VK, Margolin AA, Grandori C, Kemp CJ, Mendez E.

Functional precision medicine identifies novel druggable targets and therapeutic options in head and neck cancer. *Clinical Cancer Research*. 2018. PMID 29599409.

17. Pauli C\*, Hopkins BD\*, Prandi D, **Shaw R**, Fedrizzi T, Sboner A, Sailer V, Augello M, Puca L, Rosati R, McNary TJ, Churakova Y, Cheung C, Triscott J, Pisapia D, Rao R, Mosquera JM, Robinson B, Faltas BM, Emerling BE, Gadi VK, Bernard B, Olivier E, Beltran H, Dimichelis F, Kemp CJ, Grandori C, Cantley L, Rubin MA. Personalized in vitro and in vivo cancer models to guide precision medicine. *Cancer Discovery*. 2017. PMID 28331002.

## ABSTRACTS and POSTER PRESENTATIONS

1. **Shaw R**, Yoon JJ, Johnston H, Davidson MB, Siddon AJ, Shallis RM, Chen EC, Burkart M, Oh TS, Iyer SG, Madarang E, Muthiah C, Kassner J, Rampal RK, Murthy GSG, Bradley T, Abaza Y, Garcia JS, Gupta V, Pettit KM, Odenike O, Patel AA. Assessing acute myeloid leukemia-based risk stratification criteria in patients with accelerated/blast-phase myeloproliferative neoplasms treated with less-intensive therapy. University of Chicago Janet Rowley Research Day. 2025.
2. **Shaw R**, Albarillo F. Assessing the predictive value of methicillin-resistant *Staphylococcus aureus* nares colonization amongst transplant recipients and patients with neutropenia. Loyola University Medical Center Resident Research Symposium. 2024.
3. **Shaw R**. Multicenter analysis of the risk of malignancy following adult solid organ transplant. Loyola University Medical Center Resident Research Symposium. 2023.
4. Roloff GW, **Shaw R**, O'Connor TE, Drazer MW. Stagnation in quality of next-generation sequencing assays for the diagnosis of hereditary hematopoietic malignancies. American Society of Hematology Annual Meeting and Exposition. 2022.
5. Raman R, Villefranc, Ullmann T, Thiesmeyer J, Anelli V, Pauli C, Bareja R, Eng KW, Dorsaint P, Wilkes DC, Beg S, **Shaw R**, Churchill M, Gumpeni N, Scognamiglio T, Rubin M, Grandori C, Mosquera J, Dephore N, Sboner A, Elemento O, Houvras Y. Uncovering the mechanism of adaptive resistance to RET inhibitors in RET rearranged thyroid cancer. *Cancer Research*. 2021.
6. **Shaw R**, Swan H. Automating medical school track assignments using the Hungarian algorithm. University of Rochester School of Medicine and Dentistry Student Research Symposium. 2020.
7. Schaub FX, Maisel S, **Shaw R**, Rosati R, Bridgwater C, Churchill M, Diaz R, Murphy ST, Pereira S, Kemp CJ, Gadi VK, Grandori C. A CLIA-certified high-throughput drug screening platform for ovarian cancer to inform personalized cancer care and discover novel combinations. 12<sup>th</sup> Biennial Ovarian Cancer Research Symposium. 2019.
8. Shigeta S, **Shaw R**, Moser R, Gurley K, Lui G, Grandori C, Kemp CJ. Targeting bromodomain proteins as a therapeutic strategy for clear cell carcinoma of the ovary. 12<sup>th</sup> Biennial Ovarian Cancer Research Symposium. 2019.
9. Swan HA, Churchill MJ, Rosati R, Schaub FX, **Shaw R**, Watt RM, Mendez E, Kemp CJ, Gadi VK, Murphy SA, Bernard B, Diaz RL, Pereira SC, Grandori C. Personalization of cancer treatments with a CLIA-certified high-complexity and high-throughput drug sensitivity test. AACR Annual Meeting. 2018.
10. Swan HA, Rosati R, Bridgwater C, Churchill MJ, Watt RM, **Shaw R**, Murphy SA, Diaz RL, Pereira SC, Schaub FX, Grandori C. Personalized medicine: A CLIA-certified high-throughput drug screening platform for ovarian cancer. AACR Annual Meeting. 2018.
11. Churchill MJ, Schaub FX, Swan HA, Rosati R, Yan F, **Shaw S**, Gurley KE, Diaz RL, Pereira SC, Grandori C, Kemp CJ, Gadi VK. Patient derived tumor organoids identify actionable targets in heavily pretreated metastatic breast cancer patients. AACR Annual Meeting. 2018.

12. Schaub FX, Churchill MJ, Swan HA, Rosati R, Watt RM, **Shaw R**, Murphy SA, Diaz RL, Pereira SC, Grandori C. Accelerating drug development with a CLIA approved functional test using patient derived organoids. AACR Annual Meeting. 2018.
13. Puca L, Bareja R, **Shaw R**, Karthaus W, Gao D, Pauli C, Mosquera J, Cyrta J, Rosati R, Rao R, Sboner A, Grandori C, Inghirami G, Chen Y, Rubin MA, Beltran H. Patient-derived tumor organoids of neuroendocrine prostate cancer. Cancer Research. 2017.
14. **Shaw R**, Richards H, Rosati R, Nikolova O, Bernard B, Ligon K, Swisher E, Goff B, Mendez E, Kemp CJ, Gadi VK, Grandori C. A menu for personalized targeted therapy: Functional screens on primary solid tumors. Keystone Symposia for Personalized Medicine. 2016.

## ORAL PRESENTATIONS

---

1. **Shaw R**. Frontline treatment of mantle cell lymphoma. University of Chicago Fellow Conference. 2025.
2. **Shaw R**. WWPODD: Urothelial Carcinoma. University of Chicago Fellow Case Conference. 2025.
3. **Shaw R**. Informed consent: cancer screening and its associated risks. Endeavor Health NorthShore Oncology Grand Rounds. 2024.
4. **Shaw R**. Why cancer screening doesn't save lives. Loyola University Medical Center Clinical Pathology Conference. 2024.
5. **Shaw R**. Pacemakers, endocarditis, and sympathetic cardiac acute pulmonary edema. Loyola University Medical Center Autopsy Conference. 2022.
6. **Shaw R**. Streptococcus gallolyticus endocarditis and the risk of malignancy. Edward Hines VA General Medicine Morning Report. 2022.
7. **Shaw R**, Vuyls S, Farhan S, Orgueira AM, Nastoupil L, Hossain N. Stacking machine learning algorithms for predicting toxicity and clinical outcomes in DLBCL and B-ALL patients treated with CAR-T therapy: an analysis of the CIBMTR registry. ASTCT/CIBMTR Tandem Meetings. 2022.
8. **Shaw R**. Augmentin-associated acute liver failure. LUMC General Medicine Morning Report. 2022.
9. **Shaw R**. Clinical utility of methicillin-resistant staphylococcus aureus nares screening. Loyola University Medical Center Clinical Question Conference. 2022.
10. **Shaw R**. Acute mental status changes in a kidney transplant recipient. Edward Hines VA General Medicine Morning Report. 2022.
11. **Shaw S**, Kemp CJ, Grandori C. Functional genomics of patient-derived ovarian cancer cells identify clinically relevant rucaparib-drug combinations. Cancer Targets Discovery and Development (CTD<sup>2</sup>, NCI) network site meeting. 2018.
12. **Shaw R**, Diaz RL, Churchill M, Schaub FX, Rosati R, Bernard B, Gadi VK, Mendez E, Kemp CJ, Grandori C. Combining genomic characterization and pharmacogenomics of patient-derived organoids for personalized medicine. Institute for Systems Biology. 2018.
13. **Shaw R**, Kemp CJ, Grandori C. High-throughput small molecule screening using patient-derived organoids for personalized medicine. Cancer Targets Discovery and Development (CTD<sup>2</sup>, NCI) network site meeting. 2017.
14. **Shaw R**, Diaz R, Goff B, Swisher EM, Kemp CJ, Grandori C. Functional genomics to identify novel PARP-inhibitor-drug combinations in ovarian carcinoma. Institute for Systems Biology. 2017.

## HONORS and AWARDS

---

AACR/ASCO Methods in Clinical Cancer Research Workshop

2025

Resident Recognition Award   Loyola University Medical Center	2023
Research Scholar Award   Loyola University Medical Center	2022, 2023, 2024
Robert I. Weed Research Fellowship in Hematology   URSMD	2018
Young Scientist Training Award   SEngine Precision Medicine	2015, 2016, 2017
Undergraduate Research Award   Whitman College	2011, 2012, 2013
Academic All-American   NCAA DIII Collegiate Soccer	2011, 2012

## **CERTIFICATIONS and LICENSES**

---

- Internal Medicine Board Certification
- Basic Life Support and Advanced Cardiac Life Support
- Point of Care Ultrasound, Central line placement, Arterial line placement, Bone marrow biopsy, Lumbar puncture and IT chemo administration, Diagnostic and large-volume paracentesis, Oral and nasogastric intubation
- R statistical programming, Microsoft SQL, Python, Cloud computing
- Ad hoc peer reviewer for Scientific Reports, BMC Cancer, Blood Advances, Cancer Immunology Research, Clinical Cancer Research